Shanghai Henlius Biotech, Inc. (2696.HK) Stock

About Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, and HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical Development Co., Ltd.

Shanghai Henlius Biotech, Inc. is led by CEO Jun Zhu, employs 4,082 people, headquartered in Shanghai, CN, publicly traded since 2019.

Shanghai Henlius Biotech, Inc. (2696.HK) stock trades at $50.75 with a market capitalization of $27.67B. The stock is valued at a price-to-earnings (P/E) ratio of 28.84, price-to-book of 5.21, price-to-sales of 3.72. Over the past 52 weeks the stock has ranged between $47.62 and $87.10, and currently trades 41.7% below its 52-week high.

On profitability, Shanghai Henlius Biotech, Inc. generates a return on equity (ROE) of 21.83%, above the typical market range of roughly 12-15%, an operating margin of 14.18%, a net profit margin of 11.67%.

The balance sheet shows a debt-to-equity ratio of 0.87, a current ratio of 0.78.

2696.HK has an average daily trading volume of 938,533 shares, a beta of 0.51 (historically less volatile than the overall market), 0.35B shares outstanding.

Official website: www.henlius.com